cGxP.wire https://validator.w3.org/feed/docs/rss2.html Novo Nordisk Launches Novo Rebrand and New Corporate Culture Telix Gains FDA Approval for Pixclara in Glioma Imaging Pharmazz Gains FDA Orphan Designation for Sovateltide in NHIE Corbus Advances CRB-913 Toward Phase 2 in Obesity Debut Develops Biotech Ingredient for Hyperpigmentation Care Castle Biosciences Shows TissueCypher Improves Barrett’s Care Nasus Pharma Advances NS002 Toward Pivotal Anaphylaxis Study Eli Lilly to Present New Cardiometabolic Data at EASD 2026 Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer Lundbeck Completes Enrollment in Phase III Dravet Trial Organon’s MIUDELLA FDA Review Advances Hormone-Free IUD Consano Bio Announces Peer-Reviewed Nonclinical Research Supporting Therapeutic Potential of C-1101 in Chronic Sciatica GSK to Acquire Chimagen TCE for Multiple Myeloma Inductive Bio Launches Indy AI Assistant for Drug Discovery Abbott Resolves 2022 Infant Formula Claims Through DOJ Deal Accro Bioscience Advances Rare Disease Drug Development Aignostics Launches PathoSearch for AI-Driven Pathology Case Whitehawk Therapeutics’ PTK7 Data Support ADC Development Telomir Advances Telomir-Zn in Human and Canine Osteosarcoma Bright Path Labs Receives FDA AMT Designation for Medicines Armata’s AP-SA02 Receives FDA Breakthrough Designation Evaxion Expands AI-Immunology Platform Into Autoimmune Disease Santa Ana Bio Advances SAB01 Into Phase 1 Tris Pharma Expands QuilliChew ER With 30-Count Bottle Tenaya Therapeutics Gains RMAT Designation for TN-401 Sanofi and Cheplapharm Form Strategic Mature Medicines Partnership Biofrontera Gains FDA Approval for Ameluz in Basal Cell Carcinoma Revolution Medicines Gains FDA Breakthrough Designation for RASONQUE Sionna Advances SION-451 and SION-2222 Into Phase 2a Agomab Advances AGMB-447 Into Phase 2 for IPF J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer AbelZeta’s C-CAR168 Receives FDA IND Clearance Curium Gains FDA Approval for BEXLUTRY in GEP-NETs TuHURA’s TBS-2025 Receives FDA IND Clearance for AML Clearmind Medicine Advances CMND-100 Into AUD Clinical Trial Quantum BioPharma Advances Lucid-MS Toward Phase 2 in MS Pharming Gains FDA Approval for Pediatric Joenja in APDS Amgen’s IMDELLTRA Gets Reduced FDA Monitoring Time Bausch + Lomb Gains CE Mark for SeeLyra Femtosecond Laser GSK’s Jideytro Shows 94% Response in ROS1 Lung Cancer Roche’s Tam-Peli Shows Survival Benefit in Relapsed SCLC Cyllene Therapeutics’ EG110A Gets FDA RMAT Designation Takeda Zasocitinib Gets FDA Priority Review for Psoriasis AstraZeneca and Daiichi Sankyo’s Enhertu Delivers 14.3-Month PFS in HER2-Mutant NSCLC GSK’s Ris-Rez Cuts Death Risk in Relapsed SCLC Eloxx Begins Phase 2b Study of Exaluren in Alport Syndrome AstraZeneca’s Tagrisso Delivers 8-Year Survival in Lung Cancer Lundbeck Gains FDA Orphan Drug Status for Asedebart Nutromics Receives FDA Breakthrough Device Designation NRx Pharmaceuticals Deploys Robotic TMS Across HOPE Clinics